AiCella

About AiCella

Aicella develops AI-driven tools for CAR-T therapy process optimization, utilizing a data dashboard that correlates critical process parameters with patient responses. This approach addresses inefficiencies in cell therapy R&D, ensuring compliance with Good Manufacturing Practices and facilitating smoother transitions from research to clinical applications.

```xml <problem> CAR-T cell therapy development faces challenges in identifying critical process parameters that reliably predict patient responses, leading to inefficiencies in R&D and hindering the transition from research to clinical applications while maintaining Good Manufacturing Practices (GMP). Traditional methods often lack the ability to uncover complex relationships between process parameters and patient outcomes. </problem> <solution> Aicella provides an AI-driven data dashboard, Aicella InsightsTM, that correlates critical process parameters with patient responses to optimize CAR-T cell therapy development. The platform leverages machine learning and deep learning algorithms to analyze real-world data, providing insights into process parameters that dictate treatment success. Aicella's comprehensive offering includes GMP-oriented process development, verification of AI-generated process models in their own lab, and standard operating procedures (SOPs) with recommended best practices. They also offer tech transfer assistance to Contract Development and Manufacturing Organizations (CDMOs) and support Investigational New Drug (IND) application filings. </solution> <features> - Interactive AI/ML data dashboard summarizing critical process parameters correlated with patient responses - GMP-oriented process development to facilitate the transition from research to clinical applications - Verification of AI-generated process models in-house - Generation of standard operating procedures (SOPs) with recommended best practices - Assistance with tech transfer to CDMOs - Support for Investigational New Drug (IND) application filings - Intellectual property filing support based on AI-driven elucidation of process development </features> <target_audience> Aicella's primary customers are pharmaceutical companies, biotech firms, research institutions, and academic centers engaged in CAR-T therapy development. </target_audience> ```

What does AiCella do?

Aicella develops AI-driven tools for CAR-T therapy process optimization, utilizing a data dashboard that correlates critical process parameters with patient responses. This approach addresses inefficiencies in cell therapy R&D, ensuring compliance with Good Manufacturing Practices and facilitating smoother transitions from research to clinical applications.

Where is AiCella located?

AiCella is based in Escondido, United States.

When was AiCella founded?

AiCella was founded in 2023.

How much funding has AiCella raised?

AiCella has raised 170000.

Who founded AiCella?

AiCella was founded by Geoffrey Stephens.

  • Geoffrey Stephens - CEO
Location
Escondido, United States
Founded
2023
Funding
170000
Employees
3 employees
Looking for specific startups?
Try our free semantic startup search

AiCella

Score: 54/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Aicella develops AI-driven tools for CAR-T therapy process optimization, utilizing a data dashboard that correlates critical process parameters with patient responses. This approach addresses inefficiencies in cell therapy R&D, ensuring compliance with Good Manufacturing Practices and facilitating smoother transitions from research to clinical applications.

aicella.io300+
Founded 2023Escondido, United States

Funding

$

Estimated Funding

$170K+

Team (<5)

Geoffrey Stephens

CEO

Company Description

Problem

CAR-T cell therapy development faces challenges in identifying critical process parameters that reliably predict patient responses, leading to inefficiencies in R&D and hindering the transition from research to clinical applications while maintaining Good Manufacturing Practices (GMP). Traditional methods often lack the ability to uncover complex relationships between process parameters and patient outcomes.

Solution

Aicella provides an AI-driven data dashboard, Aicella InsightsTM, that correlates critical process parameters with patient responses to optimize CAR-T cell therapy development. The platform leverages machine learning and deep learning algorithms to analyze real-world data, providing insights into process parameters that dictate treatment success. Aicella's comprehensive offering includes GMP-oriented process development, verification of AI-generated process models in their own lab, and standard operating procedures (SOPs) with recommended best practices. They also offer tech transfer assistance to Contract Development and Manufacturing Organizations (CDMOs) and support Investigational New Drug (IND) application filings.

Features

Interactive AI/ML data dashboard summarizing critical process parameters correlated with patient responses

GMP-oriented process development to facilitate the transition from research to clinical applications

Verification of AI-generated process models in-house

Generation of standard operating procedures (SOPs) with recommended best practices

Assistance with tech transfer to CDMOs

Support for Investigational New Drug (IND) application filings

Intellectual property filing support based on AI-driven elucidation of process development

Target Audience

Aicella's primary customers are pharmaceutical companies, biotech firms, research institutions, and academic centers engaged in CAR-T therapy development.